MEDI 23-Multivalent muscarinic antagonists for the treatment of overactive bladder (OAB)

被引：0
|
作者：
Hughes, Adam D. [1 ]
Chin, Kay H. [2 ]
Hegde, Sharath S. [3 ]
Husfeld, Craig O. [1 ]
Jasper, Jeffrey R. [2 ]
Ji, Yuhua [1 ]
King, Kristin E. [2 ]
Lee, Tae Weon [2 ]
Li, Li [1 ]
Mammen, Mathai [2 ]
McNamara, Alexander J. [3 ]
Mischki, Trevor K. [1 ]
Obedencio, Glenmar P. [3 ]
Pulido-Rios, Tess [3 ]
Steinfeld, Tod [2 ]
Sweazey, Shelley M. [3 ]
Wilson, Richard D. [1 ]
机构：
[1] Theravance Inc, Med Chem, San Francisco, CA 94080 USA
[2] Theravance Inc, Mol & Cellular Biol, San Francisco, CA 94080 USA
[3] Theravance Inc, Pharmacol, San Francisco, CA 94080 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2007年 / 234卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
23-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Treatment of the overactive bladder with tolterodine, a new muscarinic receptor antagonist
    Messelink, EJ
    BJU INTERNATIONAL, 1999, 83 : 48 - 52
  • [22] Novel sulfonyldihydropyridine potassium channel openers with potential utility in the treatment of overactive bladder (OAB).
    Drizin, I
    Altenbach, RJ
    Bai, H
    Brune, M
    Buckner, SA
    Chen, YY
    Coghlan, MJ
    Gopalakrishnan, M
    Gregg, R
    Kort, ME
    Kym, P
    Sullivan, JP
    Tang, R
    Turner, S
    Zhang, H
    Carroll, WA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 222 : U673 - U673
  • [23] Intravesical electrical stimulation (IVES) treatment for overactive bladder syndrome (OAB): A pilot study
    Yune, J. J.
    Shen, J.
    Hardesty, J.
    Kim, J.
    Siddighi, S.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2016, 214 (04) : S496 - S496
  • [24] A historical perspective on anticholinergics in overactive bladder (OAB) treatment: "Foundations, current practices, and future
    Ochoa, D. Carolina
    Bouchard, Beatrice
    Abrams, Paul
    CONTINENCE, 2024, 12
  • [25] Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB?
    Frankel, Jeffrey
    Staskin, David
    Varano, Susann
    Newman, Diane K.
    Gregg, Steven G.
    Owens-Grillo, Janet
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (09)
  • [26] COST-EFFECTIVENESS OF TOLTERODINE AS TREATMENT FOR OVERACTIVE BLADDER (OAB) IN ADULT MEXICAN PATIENTS
    Arreola-Ornelas, H.
    Rosado-Buzzo, A.
    Garcia-Mollinedo, M.
    Camacho-Cordero, L.
    Mucino-Ortega, E.
    Mould-Quevedo, J. F.
    Galindo-Suarez, R. M.
    VALUE IN HEALTH, 2011, 14 (03) : A76 - A76
  • [27] Psychometric Validation of the Overactive Bladder Satisfaction With Treatment Questionnaire (OAB-SAT-q)
    Margolis, Mary Kay
    Fox, Kathleen M.
    Cerulli, Annamaria
    Ariely, Rinat
    Kahler, Kristijan H.
    Coyne, Karin S.
    NEUROUROLOGY AND URODYNAMICS, 2009, 28 (05) : 416 - 422
  • [28] Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome
    Michel, Martin C.
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (10) : 1787 - 1796
  • [29] Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity
    Glavind, Karin
    Chancellor, Michael
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2011, 22 (08) : 907 - 917
  • [30] Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity
    Karin Glavind
    Michael Chancellor
    International Urogynecology Journal, 2011, 22 : 907 - 917
12345